Prot# 4522US/0011: Rndomzd, Dbl-Bld, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (Crestor®) 20mg in Primary Prevention of Cardiovascular Events Among Subjects w/ Low Levels of LDL-Cholesterol & Elevated Levels of C-Reactive Protein

Project: Research project

Project Details

StatusFinished
Effective start/end date7/22/03 → 5/27/10

Funding

  • PPD Development (4522US/0011)
  • AstraZeneca Pharmaceuticals LP (4522US/0011)